Bausch Health Companies Inc. (BHC): what the price requires

At today's price, Bausch Health Companies Inc. (BHC) is priced for +18.6% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-19 · Source: https://boothcheck.com/report/BHC

Headline

FieldValue
TickerBHC
CompanyBausch Health Companies Inc.
Current price$4.88/sh
CompositionPharmaceuticals 46% / Devices 24% / OTC 20% / Branded and Other generics 9% / Other revenues 1%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin today3.9%
Implied growth18.6%
Multiple paid40x operating income

Solve inputs: computed at a 7% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~10.3pp (computed at the 7% minimum rate; the CAPM rate 4% sits below it).

Reconcile: at the x-ray's 9.3% required return this reads ~8.2 years; the models below use their own rates.

How unusual the bet is: within-range

ReferenceValue
vs own history+0.63σ
cohort percentile (of 113 peers)89
sustained it ~5 years at this level42%
implied end-window share0%

Valuation X-Ray

The price is justified by relative-multiple.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset—0—
Earnings—0—
Relative0.05x1justifies
Growth—0—

Families that justify the price: Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 2.1%); the inversion above states its own rate.

Per-Model Detail (n=1)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth——no—
DCF Exit MultipleGrowth$36.230.13xnoExit EV/EBITDA: 23.1x / 25.1x / 27.1x (bear / base = today's held flat / bull), 6yr
Relative ValuationRelative$97.600.05xyesP/S fallback (negative EPS): Sector P/S 4.0x × TTM revenue — excluded from consensus
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset——no—
Two-Stage Excess ReturnAsset——no—
Discounted Future Market CapGrowth$3.921.24xnoRev $10.5B, growth 8% (input: historical growth; tapered), Terminal P/S: 0.1x / 0.2x / 0.2x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings$93.080.05xnoNormalized EBIT (5y avg op income, one-time charges added back) $1.48B × (1−21%) / WACC 2.1% → EPV (no growth)
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative$0.01488.00xyesEBITDA $0.88B × sector EV/EBITDA 16.0x (excluded from median)
FCF YieldEarnings$0.01488.00xyesFCF $1028.0M / Kₑ 9.3% — zero-growth perpetuity (excluded from median)
SBC-Adj FCF YieldEarnings$0.01488.00xyesSBC-adj FCF $0.80B (FCF $1.03B − SBC $0.23B) capitalized at Kₑ (excluded from median)
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative$112.990.04xnoRevenue $10.53B × sector P/S 4.0x
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$19.5b
Net debt / NOPAT (after-tax)63.34x
Net debt / operating income (pre-tax)50.04x
Interest coverage0.2x
Share count CAGR (dilution)0.8%
Burning cashno

Bullet Takeaways

Bull Case

The balance sheet is where the Bausch Health story is won or lost, and the first thing to understand is that at a $4.76 share price, the equity is a small, highly geared claim on a much larger enterprise. That is exactly why the bull case can work: a modest improvement in the business or a modest reduction in debt flows disproportionately to the thin equity layer. Management is making progress on both. The company reduced net debt by over $100 million in the quarter, and it generates real operating cash, guiding to full-year adjusted operating cash flow of $1.2 to $1.275 billion. For a leveraged equity, debt paydown is the mechanism that transfers enterprise value from creditors to shareholders over time.

The operating businesses are growing faster than their reputation suggests. First-quarter revenue rose 12% on a reported basis and 7% organically to $2.524 billion, and adjusted EBITDA jumped 27% to $837 million. The portfolio spans gastrointestinal drugs led by the Salix franchise, the Solta aesthetic-devices business, international and over-the-counter products, and the separately managed Bausch + Lomb eye-health business. The 10-K notes the Bausch + Lomb segment is itself diversified, with no single product group representing 10% or more of its segment revenues on revenue of $5,101 million, which is a meaningful, independently valuable asset sitting inside the structure.

The hidden value is the Bausch + Lomb stake. Bausch Health owns a large majority of the publicly traded eye-health company, and the long-discussed separation of that stake is the catalyst that could de-lever the parent in one move. If management can monetize or distribute Bausch + Lomb at a fair value, the proceeds attack the debt directly, and what remains is a smaller, growing specialty-pharma business with a far more manageable capital structure. The bull case is a sum-of-the-parts and de-leveraging bet: a growing operating base, real cash flow servicing the debt, and a valuable subsidiary whose separation could reset the whole equation.

Bear Case

The structural truth a Bausch Health holder cannot avoid is that this is a leveraged equity stub, and the leverage is extreme. Long-term debt principal sits near $20 billion, roughly thirty times trailing operating income, and interest coverage is below one, meaning operating income does not cover interest expense on a trailing basis. At that level of leverage, the equity is not a claim on a business so much as an option on the business outrunning its debt, and options expire. Any operating stumble, refinancing at higher rates, or covenant pressure lands first and hardest on the shareholders, because the creditors are ahead of them in line. The $4.76 price (June 27, 2026) is low for a reason: the market is pricing real risk that the equity value gets compressed if the de-leveraging does not proceed.

The Salix impairment is a warning about the durability of the asset base. The company recorded a $1.426 billion goodwill impairment in the Salix reporting unit after a Phase 3 trial failure, driving a net loss of $1.431 billion for the quarter. Salix, anchored by Xifaxan, is the most important growth engine in the pharmaceuticals segment, and Xifaxan faces a patent and generic-competition cliff that has been litigated for years. A pipeline setback at the franchise that has to carry the company is exactly the kind of event that erodes the asset value standing behind the debt. The 10-K acknowledges the reliance on its R&D organization to build-out and refresh our product portfolio, and refresh is precisely what just failed.

The valuation looks distorted because the earnings are. At about 40 times trailing operating income, the multiple is high not because the equity is expensive on a normalized basis, but because operating margin is compressed to 5.6% by the debt load and impairments, and only the relative-multiple method reaches the price at all. The implied assumption is roughly 18.5% annual operating-profit growth, a demanding pace for a company fighting a patent cliff and a debt mountain at once. The Bausch + Lomb separation that the bull case relies on has been delayed repeatedly and is itself constrained by debt covenants. The bear is straightforward: a tiny equity sliver on a $20 billion debt stack, a key franchise just impaired, and a de-leveraging catalyst that keeps slipping.

Valuation

Bausch Health's valuation has to start with the capital structure, because the equity is a small residual on a very large enterprise. Long-term debt principal near $20 billion dwarfs both the equity market value and the operating income, so almost all of the enterprise value belongs to creditors. The $4.76 share price reflects what is left for shareholders after the debt, which is why a small change in the business or the debt moves the equity sharply in either direction.

The method read is unusual because the earnings are so distorted. At about 40 times trailing operating income, the multiple is high, but operating margin is compressed to 5.6% by interest costs and the recent impairment, so the multiple is high for the same reason the equity is risky. Only the relative-multiple method reaches the price; with operating income this thin relative to debt, the asset, earnings-power, and growth lenses have little to anchor on. The implied requirement, roughly 18.5% annual operating-profit growth, is the market pricing a recovery and de-leveraging, not the current run-rate. The honest framing is that this is a credit-driven equity: the value depends on debt reduction and asset separations more than on an operating multiple.

Solvency is not a footnote here; it is the entire thesis, and the numbers are stark. Net debt near $19.5 billion at roughly thirty times operating income, with interest coverage below one, is the dominant fact, and the recent $1.4 billion Salix impairment removed value from the asset base standing behind that debt. The downside is genuinely a debt-driven equity impairment if the business cannot grow into its obligations or refinance on acceptable terms. The Bausch + Lomb stake is the offsetting asset, and its separation is the lever that could reset the structure. A buyer at this price is making a leveraged, event-driven bet on de-leveraging and a successful separation, not a conventional valuation call on a healthy business.

Catalysts

Bausch Health's first quarter combined operating growth with a large accounting charge. Revenue rose 12% on a reported basis and 7% organically to $2.524 billion, and adjusted EBITDA increased 27% to $837 million. But the company recorded a $1.426 billion goodwill impairment in its Salix reporting unit following a Phase 3 trial failure, producing a net loss of $1.431 billion for the quarter against an $86 million loss a year earlier.

The capital structure remains the central story. Long-term debt principal stood at $20,212 million, though the company reduced net debt by more than $100 million in the quarter, evidence of steady progress on the de-leveraging that the equity thesis depends on. Management's guidance separates the businesses cleanly: full-year 2026 adjusted EBITDA excluding Bausch + Lomb is expected between $2.875 billion and $2.95 billion, with adjusted operating cash flow of $1.2 to $1.275 billion.

The signposts ahead are concentrated in debt and structure. Progress on refinancing maturities, covenant compliance, and above all the long-anticipated separation of the majority-owned Bausch + Lomb stake are the events that would most move the equity. On the operating side, the trajectory of the Salix and Xifaxan franchise after the trial setback, and the durability of the growing international and aesthetics lines, determine whether the operating base can grow into the debt while the capital structure is addressed.

Peer Cohorts (Per Segment, With Filing Citations)

Salix (reported)

Solta Medical (reported)

Diversified (reported)

Bausch + Lomb (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Bausch Health Q1 2026 results

View the full interactive BHC report on boothcheck